戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 essential for the formation of premetastatic osteolytic lesions.
2 ne among those increased in MM patients with osteolytic lesions.
3 s more Notch3, than tumor cells that produce osteolytic lesions.
4 and B-symptoms and was found to have diffuse osteolytic lesions.
5 ssion, radiation or surgery to bone, and new osteolytic lesions.
6  and decrease the progression of established osteolytic lesions.
7 mall group of Tax(+) animals presenting with osteolytic lesions.
8 nificantly prevented the formation of severe osteolytic lesions.
9 ant in the resulting suppression of skeletal osteolytic lesions.
10 cell line, C4-2B, induces mixed osteoblastic/osteolytic lesions.
11 te, significantly delayed the progression of osteolytic lesions.
12 alyses to identify molecular determinants of osteolytic lesions.
13 ue associated with progressive periarticular osteolytic lesions.
14  insipidus, bilateral ear discharge, and new osteolytic lesions.
15 with metastatic breast cancer who have known osteolytic lesions.
16 n myeloma cells inhibited the development of osteolytic lesions.
17 cer frequently metastasizes to bone, causing osteolytic lesions.
18 , with 11% (eight of 70) of images including osteolytic lesions.
19 ells into tibial bone and the development of osteolytic lesions.
20 ctures (45 [5%] vs 66 [7%]; p=0.04), and new osteolytic lesions (46 [5%] vs 95 [10%]; p<0.0001).
21                          After treatment, 58 osteolytic lesions (80.5%) became [(18)F]FDG negative an
22    CCR1 activation leads to the formation of osteolytic lesions and facilitates tumor growth.
23 g modality, its low sensitivity in detecting osteolytic lesions and inability to evaluate response to
24 toma cells recruited osteoclasts to generate osteolytic lesions and invade the bone matrix.
25 use model of bone metastasis, A77636 reduced osteolytic lesions and prevented mechanical weakening of
26  progeria-like disease phenotypes, including osteolytic lesions and rib fractures, osteoporosis, slow
27 evented splenomegaly, limited development of osteolytic lesions, and concomitantly reduced tumor grow
28  turn a suppressor of osteoclastic activity, osteolytic lesions, and disease burden in a preclinical
29  correlated with markers of bone resorption, osteolytic lesions, and markers of disease activity.
30                                              Osteolytic lesions are a painful consequence of metastas
31  and radiological presentations, among which osteolytic lesions are the most widespread, being the ri
32 ss of Notch3 in osteoblastic tumors enhanced osteolytic lesion area and decreased osteoblastogensis.
33  Notch3 (NICD3) in osteolytic tumors reduced osteolytic lesion area and enhanced osteoblastogenesis,
34 ue involvement, presence of an abscess or an osteolytic lesion around causative tooth.
35 r survival, a smaller tumor burden, and less osteolytic lesions, as compared with mice bearing contro
36 s that these compounds reduce PTHrP-mediated osteolytic lesions associated with metastatic human brea
37 C4-2B's ability to induce mixed osteoblastic/osteolytic lesions, C4-2B cells were stably transfected
38 , our findings suggest a novel mechanism for osteolytic lesions caused by cancer cells metastasizing
39  treatment completely prevented radiographic osteolytic lesions caused by human MDA-MB-231 breast can
40 tumor primarily metastasizes to bone to form osteolytic lesions, causing severe pain and pathological
41                            In cancer-induced osteolytic lesions, cleavage of receptor activator of nu
42  osteolytic lesion; semiquantitative score = osteolytic lesion count) were assessed by three radiolog
43 l analysis at weekly intervals revealed that osteolytic lesions developed in the control tibias by 2
44  mechanisms of inhibiting myeloma growth and osteolytic lesion development.
45 r interactions governing the early events of osteolytic lesion formation are currently unclear.
46                                Surprisingly, osteolytic lesion formation was greatest in animals lack
47 tumours or systemic delivery of LOX leads to osteolytic lesion formation whereas silencing or inhibit
48 issemination in the bone marrow and enhanced osteolytic lesion formation, irrespective of HIF-1 Conve
49 tion of LOX activity abrogates tumour-driven osteolytic lesion formation.
50 er cells in the bone marrow and tumor-driven osteolytic lesion formation.
51  the progression of soft tissue necrosis and osteolytic lesion formation.
52     Anti-Wnt5a therapy may prevent or reduce osteolytic lesions found in ATL patients and improve the
53           Multiple myeloma is incurable once osteolytic lesions have seeded at skeletal sites, but fa
54 ecrete osteoclastogenic factors that promote osteolytic lesions; however, the identity of these facto
55 the transcriptomic profile of the periapical osteolytic lesion in a mouse model of apical periodontit
56 s may correlate with a propensity to develop osteolytic lesions in arthritis.
57 pose tissue, micrognathia, osteoporosis, and osteolytic lesions in bone.
58 reast cancer cells can prevent production of osteolytic lesions in bone.
59 lopecia, micrognathia, dental abnormalities, osteolytic lesions in bones, and osteoporosis, which are
60 at MMP-13 is critical for the development of osteolytic lesions in MM and that targeting the MMP-13 p
61  gradient-echo black bone [BB]) in detecting osteolytic lesions in MM using whole-body CT as the refe
62 trated high diagnostic accuracy in detecting osteolytic lesions in MM.
63 activity of osteoblasts (OBs) contributes to osteolytic lesions in multiple myeloma (MM).
64  very effective in limiting the formation of osteolytic lesions in PC-3 implanted tibias by inhibitin
65                                              Osteolytic lesions in the ribs led to spontaneous bone f
66 on of DKK1 by MM cells likely contributes to osteolytic lesions in this disease by inhibiting Wnt sig
67 n several human cancer cell lines that cause osteolytic lesions in vivo and produce PTHrP (MDA-MB-231
68 ort that human neuroblastoma cells that form osteolytic lesions in vivo do not produce osteoclast-act
69  tumor cells abolishes their ability to form osteolytic lesions in vivo.
70 n osteoblastic reaction in vitro and induced osteolytic lesions in vivo.
71 nization of the bone marrow and formation of osteolytic lesions in vivo.
72  bone scans have sensitivity limitations for osteolytic lesions manifested in MM.
73 geting osteoclasts, which are upregulated in osteolytic lesions, may facilitate earlier follow-up in
74                                              Osteolytic lesions (OL) characterize symptomatic multipl
75  patients with multiple myeloma (MM) lacking osteolytic lesions (OLs), suppresses MM bone disease by
76 es that produce osteoblastic (MDA PCa 2b) or osteolytic lesions (PC-3).
77 res (categorical score = presence/absence of osteolytic lesion; semiquantitative score = osteolytic l
78 veloped hypercalcemia and significantly more osteolytic lesions than mice bearing CHO/EV tumors, with
79     Infection of the dental pulp leads to an osteolytic lesion that results from a polymicrobial infe
80 a cells in the bone marrow induces localized osteolytic lesions that rarely heal due to increased bon
81 ved to be central to the pathogenesis of the osteolytic lesion, the mechanisms by which this bacteria
82 66 as a key oncogenic driver in PCa, causing osteolytic lesions through upstream epigenetic regulatio
83                                Total area of osteolytic lesions was significantly lower in mice treat
84 ith established bone metastases, the size of osteolytic lesions was significantly reduced after 4 wee
85 acquired immune response could contribute to osteolytic lesions, we injected the periodontal pathogen
86 bone marrow plasma from femurs affected with osteolytic lesions were increased 2.5-fold over correspo
87                                  Microscopic osteolytic lesions were observed adjacent to plasma cell
88  osteolysis in mice receiving control cells, osteolytic lesions were significantly reduced following
89                                              Osteolytic lesions were successfully quantified using sm
90                                          The osteolytic lesions, which develop usually in the long bo
91  metastasis produced detectable, progressive osteolytic lesions within 3 weeks of intracardiac inject
92  those cells with increased IGF-IR form both osteolytic lesions within the tibiae and secondary tumor
93 frequently metastasize to bone, resulting in osteolytic lesions, yet the underlying mechanisms are po